Company: PSTV
Filing Date: 2025-03-14
Form Type: PRE 14A
Source: 0001140361-25-008857
Chunk: 39

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-14
Form: PRE 14A
Chunk 39
---
 issuable upon exercise of the Prefunded Warrants, Series A Warrants and Series B Warrants held by SHN are each subject to a beneficial ownership limitation of 9.99% and accordingly, not all shares underlying such warrants are reflected in the table above as being beneficially owned. |

| (6) | Reflects: (i) Great Point Capital, LLC holdings of: (A) 885,454 shares of Common Stock, (B) 3,660,000 shares of Common Stock issuable upon the exercise of Prefunded Warrants, (C) 4,545,454 shares of Common Stock issuable upon the exercise of Series A Warrants, and (D) 4,545,454 shares of Common Stock issuable upon the exercise of Series B Warrants. Gabriel Mengin and Dan Dimiero, as principals of Great Point Capital, LLC, hold voting and dispositive power over the securities held by Great Point Capital, LLC. Great Point Capital, LLC is a broker-dealer. The principal business address of Great Point Capital, LLC is 200 West Jackson Blvd., Suite 1000, Chicago, IL 60606. The shares of Common Stock issuable upon exercise of the Prefunded Warrants, Series A Warrants and Series B Warrants held by Great Point Capital, LLC are each subject to a beneficial ownership limitation of 9.99% and accordingly, not all shares underlying such warrants are reflected in the table above as being beneficially owned. |

| (7) | Reflects (i) 20,425 shares of Common Stock; (ii) 12,255 shares of Common Stock issuable upon the exercise of Series A common stock purchase warrants to purchase shares of Common Stock issued in the May Offering (the “May 2024 Series A Warrants”); (iii) 12,255 shares of Common Stock issuable upon the exercise of May 2024 Warrants; and (iv) 118,746 shares of Common Stock underlying unvested options to purchase shares of Common Stock held by Dr. Hedrick that will vest within 60 days of March 4, 2025. Dr. Hedrick is the President, Chief Executive Officer and a director of Plus Therapeutics. |

| (8) | Reflects (i) 9,815 shares of Common Stock; (ii) 4,902 shares of Common Stock issuable upon the exercise of May 2024 Series A Warrants; (iii) 4,